cilostazol has been researched along with Cirrhosis in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 7.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Cardiac fibrosis is characterized by the net accumulation of extracellular matrix in the myocardium and is an integral component of most pathological cardiac conditions." | 5.72 | Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice. ( Hada, Y; Uchida, HA; Umebayashi, R; Wada, J; Yoshida, M, 2022) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 3.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Cardiac fibrosis is characterized by the net accumulation of extracellular matrix in the myocardium and is an integral component of most pathological cardiac conditions." | 1.72 | Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice. ( Hada, Y; Uchida, HA; Umebayashi, R; Wada, J; Yoshida, M, 2022) |
| "Cilostazol is an antiplatelet agent that can induce the regression of atherosclerosis." | 1.40 | Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy. ( Narumi, S; Ohba, H; Oura, K; Sasaki, M; Terayama, Y; Uwano, I; Yamaguchi Oura, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hada, Y | 1 |
| Uchida, HA | 1 |
| Umebayashi, R | 1 |
| Yoshida, M | 1 |
| Wada, J | 1 |
| Reddy, SS | 1 |
| Agarwal, H | 1 |
| Barthwal, MK | 1 |
| Yamaguchi Oura, M | 1 |
| Sasaki, M | 1 |
| Ohba, H | 1 |
| Narumi, S | 1 |
| Oura, K | 1 |
| Uwano, I | 1 |
| Terayama, Y | 1 |
| Koh, JS | 1 |
| Yi, CO | 1 |
| Heo, RW | 1 |
| Ahn, JW | 1 |
| Park, JR | 1 |
| Lee, JE | 1 |
| Kim, JH | 1 |
| Hwang, JY | 1 |
| Roh, GS | 1 |
| Mendes, JB | 1 |
| Campos, PP | 1 |
| Rocha, MA | 1 |
| Andrade, SP | 1 |
5 other studies available for cilostazol and Cirrhosis
| Article | Year |
|---|---|
Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice.
Topics: Angiotensin II; Animals; Cilostazol; Fibrosis; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockou | 2022 |
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, A | 2018 |
Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy.
Topics: Aged; Carotid Artery Diseases; Cilostazol; Female; Fibrosis; Humans; Imaging, Three-Dimensional; Int | 2014 |
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice.
Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Cardiomyopathies; Cilostazol; Doxorubicin; | 2015 |
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.
Topics: Animals; Cilostazol; Disease Models, Animal; Fibrosis; Inflammation; Male; Mice; Mice, Inbred BALB C | 2009 |